Filtered By:
Condition: Thrombosis
This page shows you your search results in order of date. This is page number 4.
Order by Relevance | Date
Total 39172 results found since Jan 2013.
In-Hospital Venous Thromboembolism and Pulmonary Embolism After Major Urologic Cancer Surgery
CONCLUSIONS: RC, RN, and PN predisposes to a higher VTE and PE rates than RP. Moreover, among RC and RN patients with either VTE or PE, mortality is substantially higher than among their VTE or PE-free counterparts.PMID:37721691 | DOI:10.1245/s10434-023-14246-0
Source: Ann Oncol - September 18, 2023 Category: Cancer & Oncology Authors: Cristina Cano Garcia Stefano Tappero Mattia Luca Piccinelli Francesco Barletta Reha-Baris Incesu Simone Morra Lukas Scheipner Andrea Baudo Zhe Tian Benedikt Hoeh Francesco Chierigo Gabriele Sorce Fred Saad Shahrokh F Shariat Luca Carmignani Sascha Ahyai N Source Type: research
Correction: Anticoagulant Therapy for Cancer-Associated Thrombosis
Ann Intern Med. 2023 Sep 19. doi: 10.7326/L23-0345. Online ahead of print.NO ABSTRACTPMID:37722116 | DOI:10.7326/L23-0345
Source: Annals of Internal Medicine - September 18, 2023 Category: Internal Medicine Source Type: research
Melatonin as a therapeutic agent for alleviating endothelial dysfunction in cardiovascular diseases: Emphasis on oxidative stress
Biomed Pharmacother. 2023 Sep 16;167:115475. doi: 10.1016/j.biopha.2023.115475. Online ahead of print.ABSTRACTThe vascular endothelium is vital in maintaining cardiovascular health by regulating vascular permeability and tone, preventing thrombosis, and controlling vascular inflammation. However, when oxidative stress triggers endothelial dysfunction, it can lead to chronic cardiovascular diseases (CVDs). This happens due to oxidative stress-induced mitochondrial dysfunction, inflammatory responses, and reduced levels of nitric oxide. These factors cause damage to endothelial cells, leading to the acceleration of CVD progr...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - September 18, 2023 Category: Drugs & Pharmacology Authors: Xiaolu Zhang Yujia Zheng Ziyu Wang Jiali Gan Bin Yu Bin Lu Xijuan Jiang Source Type: research
Strategies for Tailored Antiplatelet Therapy After PCI: Unraveling Complexities, Embracing Nuances
Thromb Haemost. 2023 Sep 18. doi: 10.1055/a-2177-4220. Online ahead of print.ABSTRACTNot applicable.PMID:37722600 | DOI:10.1055/a-2177-4220
Source: Thrombosis and Haemostasis - September 18, 2023 Category: Hematology Authors: Davide Landolina Nicola Ammirabile Davide Capodanno Source Type: research
Mechanisms and management of the coagulopathy of trauma and sepsis: TIC, SIC, and DIC
J Thromb Haemost. 2023 Sep 16:S1538-7836(23)00702-X. doi: 10.1016/j.jtha.2023.05.028. Online ahead of print.ABSTRACTDisseminated intravascular coagulation (DIC) can occur due to different causes but commonly following sepsis. Trauma-induced coagulopathy (TIC) occurs on hospital arrival in approximately 25% of seriously injured patients that initially presents with impaired hemostasis and a bleeding phenotype that can later progress to a prothrombotic phase. Following traumatic injury, ineffective hemostasis is driven by massive blood loss, tissue damage, and hyperfibrinolysis. This initial impaired hemostasis continues unt...
Source: Thrombosis and Haemostasis - September 18, 2023 Category: Hematology Authors: Toshiaki Iba Julie Helms Matthew D Neal Jerrold H Levy Source Type: research
Long-term outcomes of prophylaxis with a recombinant factor VIII Fc or recombinant factor IX Fc in patients with hemophilia previously treated on demand
CONCLUSIONS: Findings add to existing evidence and demonstrate the clinical and HRQoL benefits of switching patients from on-demand treatment to rFVIIIFc/rFIXFc prophylaxis.PMID:37720484 | PMC:PMC10502440 | DOI:10.1016/j.rpth.2023.102163
Source: Thrombosis and Haemostasis - September 18, 2023 Category: Hematology Authors: Mar ía-Teresa Álvarez-Román Amy D Shapiro Margaret V Ragni Helena Palmborg Linda Bystrick á Johan Szamosi Sandra Casiano Herv é Chambost Source Type: research
Caplacizumab use for immune thrombotic thrombocytopenic purpura: the Milan thrombotic thrombocytopenic purpura registry
Res Pract Thromb Haemost. 2023 Aug 26;7(6):102185. doi: 10.1016/j.rpth.2023.102185. eCollection 2023 Aug.ABSTRACT•Data on caplacizumab use for thrombotic thrombocytopenic purpura (TTP) in Italy are missing.•Twenty-six Italian patients were treated with caplacizumab for an acute immune TTP episode.•Caplacizumab was effective in treating acute TTP in the Italian real-world clinical setting.•Two major bleeds leading to drug discontinuation were observed.PMID:37720483 | PMC:PMC10502422 | DOI:10.1016/j.rpth.2023.102185
Source: Thrombosis and Haemostasis - September 18, 2023 Category: Hematology Authors: Pasquale Agosti Pasqualina De Leo Marco Capecchi Barbara Ferrari Ilaria Mancini Salvatore Gattillo Silvia Maria Trisolini Erminia Rinaldi Gian Marco Podda Lucia Prezioso Prassede Salutari Luca Facchini Domenica Caramazza Giulia Tolomelli Andrea Artoni Flo Source Type: research
Health-related quality of life is impaired in bleeding disorders of unknown cause: results from the Vienna Bleeding Biobank
CONCLUSION: The impairments in HrQoL in patients with BDUC emphasize the burden of BDUC on mental and physical well-being, encouraging early recognition and better counseling of patients with BDUC.PMID:37720482 | PMC:PMC10502434 | DOI:10.1016/j.rpth.2023.102176
Source: Thrombosis and Haemostasis - September 18, 2023 Category: Hematology Authors: Dino Mehic Stephan Schwarz Ihor Shulym Cihan Ay Ingrid Pabinger Johanna Gebhart Source Type: research
Treatments for COVID-19
Annu Rev Med. 2023 Sep 18. doi: 10.1146/annurev-med-052422-020316. Online ahead of print.ABSTRACTThe treatment for COVID-19 has evolved rapidly since the start of the pandemic and now consists mainly of antiviral and immunomodulatory agents. Antivirals, such as remdesivir and nirmatrelvir-ritonavir, have proved to be most useful earlier in illness (e.g., as outpatient therapy) and for less severe disease. Immunomodulatory therapy, such as dexamethasone and interleukin-6 or Janus kinase inhibitors, are most useful in severe disease or critical illness. The role of anti-SARS-CoV-2 monoclonal antibodies has diminished because...
Source: Annual Review of Medicine - September 18, 2023 Category: General Medicine Authors: Hayden S Andrews Jonathan D Herman Rajesh T Gandhi Source Type: research
Effectiveness of Shuxuening injection in coronary heart disease: a systematic review and meta-analysis
Conclusion: SXNI can effectively improve angina symptoms, clinical efficacy, cardiac function, blood lipid indicators, and thrombosis factors of patients with CHD. However, more multi-center and large-sample studies are needed to confirm the conclusions due to the limitations of this study.Registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?RecordID=399606; Identifier: CRD42023433292.
Source: Frontiers in Pharmacology - September 18, 2023 Category: Drugs & Pharmacology Source Type: research
Evaluation of collagen turnover biomarkers as an objective measure for efficacy of treatment with rurioctocog alfa pegol in Hemophilia A patients: a secondary analysis of a randomized controlled trial
CONCLUSION: Joint improvement measured by collagen remodelling biomarkers specific to the basement membrane, interstitial matrix, and cartilage was seen with pharmacokinetics-guided prophylaxis. These collagen remodeling biomarkers warrant further exploration as biomarkers to guide treatment toward improvement in HA.PMID:37717853 | DOI:10.1016/j.jtha.2023.08.035
Source: Thrombosis and Haemostasis - September 17, 2023 Category: Hematology Authors: Tina Manon-Jensen Srilatha Tangada Cecilie Bager Pratima Chowdary Robert Klamroth Annette von Drygalski Jerzy Windyga Miguel Escobar Peder Frederiksen Werner Engl Bruce Ewenstein Morten Karsdal Source Type: research
An Update on Inflammation in Atherosclerosis: How to Effectively Treat Residual Risk
This study reviewed the contribution of inflammation to atherosclerotic cardiovascular disease (ASCVD), which has gained widespread recognition in recent years.METHODS: This critical review evaluated how recent publications and ongoing clinical trials in atherosclerotic inflammation will affect clinical care.FINDINGS: Key trials, including CANTOS (Canakinumab Anti-Inflammatory Thrombosis Outcomes Study) with canakinumab (interleukin-1β inhibition), and COLCOT (Colchicine Cardiovascular Outcomes Trial) and LoDoCo2 (Low Dose Colchicine 2) with colchicine, have shown that suppressing inflammation can improve outcomes in ASCV...
Source: Atherosclerosis - September 16, 2023 Category: Cardiology Authors: N Mohammadnia T S J Opstal S El Messaoudi W A Bax J H Cornel Source Type: research
Mikania micrantha Kunth: An Ethnopharmacological Treasure Trove of Therapeutic Potential
This study aimed at summarizing the traditional uses, phytochemical profile, and biological activities of M. micrantha based on obtainable information screened from different databases. The results suggest that fresh leaves and whole plant are frequently used in folk medicine. The plant contains more than 150 different phytochemicals under the following groups: essential oils, phenolics and flavonoids, terpenes, terpene lactones, glycosides, and sulfated flavonoids. It contains carbohydrates and micronutrients including vitamins and major and trace minerals. M. micrantha possesses antioxidant, anti-inflammatory, anti-micro...
Source: Chemistry and Biodiversity - September 16, 2023 Category: Biochemistry Authors: Muahmmad Ali Khan Dina M El-Kersh Md Shafiqul Islam Shams Ara Khan Hossam Kamli Chandan Sarkar Md Shimul Bhuia Tawhida Islam Manik Chandra Shill Glenda C Gobe Eda S önmez Gürer William N Setzer Javad Sharifi-Rad Muhammad Torequl Islam Source Type: research
